Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

ables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Scientists from the J. ... organization, published a paper today outlining new synthetic ... called diatoms. The researchers, led by first author ... Philip Weyman , Ph.D., conclude that these ... of diatom genetics and thus facilitate advances in ...
(Date:4/21/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... of MM-141, a bispecific antibody targeting IGF-1R and ErbB3.  ... Dr. Mansoor Saleh , MD at the 2015 ... Philadelphia, PA.  The trial evaluated the ... in combination with everolimus or with nab-paclitaxel and gemcitabine ...
(Date:4/21/2015)... , April 21, 2015 Ampio Pharmaceuticals, ... a scheduled investor call on Thursday, April 23, 4:30 ... the instructions as follows: Investor call ... number: (844) 789-4877 International toll number: (925) 418-7845 Participant ... advance to Tina Amirkiai , tina.amirkiai@fleishman.com . ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... that Dr. Mark W. Sawicki , ... 3rd Annual BioLogistics Summit in San ...
Breaking Biology Technology:Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... being lifted from the once unseen world of molecular activity. ... and scientists were forced to gauge the processes behind those ... that approach have become clear with the advent of technologies ... A prime example is the recent first ever direct observations ...
... , SAN DIEGO, Aug. 7 ... sales of products for the diagnosis and treatment of coronary and ... the Canaccord Adams 29th Annual Global Growth Conference on Thursday, August ... president and chief executive officer, will begin at 11:30 a.m., Eastern ...
... , CORAL GABLES, Fla., Aug. 7 Catalyst Pharmaceutical ... second quarter and six months ended June 30, 2009. , , ... For the quarter ended June 30, 2009, the Company reported a ... a net loss of $2,377,440, or $0.19 per basic and diluted share for ...
Cached Biology Technology:Growth spurts 2Growth spurts 3Growth spurts 4Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 7
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... of a TB Vaccine PDP, An Exhibitor,s Workshop at the ... 1:00-2:00 PM VENUE: 2011 AAAS ANNUAL MEETING, ,WASHINGTON CONVENTION ... an overview of the state of the global TB epidemic ... product development partnerships such as Aeras; and ways that scientists ...
... kingdom was overgrown by vines when she fell into a ... University of Wisconsin at Milwaukee received more than a million ... real vines are overtaking the American tropics. Data from eight ... "We are witnessing a fundamental structural change in the physical ...
... a human cell and a bacterial cell met at a ... numbers, much less genetic material. In more scientific terms, a ... to bacteria. Until now. Northwestern Medicine researchers have discovered ... bacterial genome in this case, Neisseria gonorrhoeae , ...
Cached Biology News:Why are vines overtaking the American tropics? 2Gonorrhea acquires a piece of human DNA 2
... regulate cell stretching or compression of a ... Computer controlled so you can precisely regulate ... to produce 64 unique strain parameters. ST-160 ... ST-150. Both models are compatible with Nikon, ...
... EasyCount ViaSure Kit is used in conjunction with ... nucleated cells automatically. The ViaSure Staining Reagent ... - Acridine Orange and Ethidium Bromide to identify ... test, while the EasyCount Slide 6 Multi-well ...
... Basic power supply are used for electrophoretic blotting ... accommodates two 7.5 x 10 cm gels and ... Bio-Ice cooling unit, buffer tank, lid with power ... power supply, 100-120 and 220-240 V, provides output ...
...
Biology Products: